Comparative Pharmacology
Head-to-head clinical analysis: DIAZEPAM INTENSOL versus DORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIAZEPAM INTENSOL versus DORAL.
DIAZEPAM INTENSOL vs DORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that potentiates GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and neuronal inhibition.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
2 to 10 mg orally 2 to 4 times daily, as needed for anxiety or muscle spasm; 10 mg orally before procedures for sedation. Maximum 40 mg/day.
15-30 mg orally at bedtime, maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is 20–50 hours (mean ~30 hours) in adults, with significant interindividual variability; prolonged in elderly, hepatic impairment, and neonates (up to 100 hours).
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Renal excretion of metabolites (primarily glucuronide conjugates) accounts for ~70% of elimination; fecal excretion accounts for ~10%; unchanged drug in urine is <1%.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Category D/X
Category C
Benzodiazepine
Benzodiazepine